- Types of Eczema
- Eczema in Children
- Living Well
- Eczema Products
- Get Involved
- For Medical Professionals
The relationship between atopic dermatitis and Staphylococcus aureus is longstanding and complex. A Dutch company is investing in a new technology that targets staph to help reduce disease severity.
In addition to conjunctivitis, a widely reported side effect of the atopic dermatitis biologic Dupixent (dupilumab), researchers report that eosinophilia and facial eczema could also be side effects.
More than two years after the FDA’s approval of the first biologic treatment for atopic dermatitis, many patients taking Dupixent report dramatic improvement in their symptoms and quality of life.
The Swiss scientists theorized that the same immune cells that protect us against the normally harmless Malassezia fungus might also play a fundamental role in triggering atopic dermatitis.
While not a cure, Orliderm™ has brought relief to hundreds of children and adults with moderate to severe atopic dermatitis.
The researchers suggest doctors combine basic skincare techniques with cutting-edge treatments to maximize the well-being of their patients.
In the “Golden Age of Eczema,” people with atopic dermatitis have more treatment options than ever before, with even more drugs making their way to pharmacy shelves.
New evidence shows that Lactobacillus-containing probiotic strains may reduce disease severity in children age 3 and under.
Dermatologists discuss the potential efficacy of prescribing an opioid antagonist to address the problem of itch in atopic dermatitis.
A new, nonsteroidal topical cream for AD called Jakafi (ruxolitinib) may soon hit pharmacy shelves.